drugset / Trial / NCT00999830
Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open randomised phase II study evaluating the anti-tumour activity, safety and pharmacology of two dose regimens of IPH2101, a human monoclonal anti-KIR antibody, in patients with multiple myeloma in stable partial response after a first line therapy.
Timeline
- Start
- 2009-09
- Primary completion
- 2012-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IPH2101 | Monoclonal antibody | 0.2 mg/kg | Intravenous |
| Subject | IPH2101 | Monoclonal antibody | 2 mg/kg | Intravenous |